Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 3/20 | 0.52 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5534979 | 0.85 | ABCC1 (0.58) | MAPTGAASMN1; SMN2POLBABCC1 | |
| SCHEMBL5538373 | 0.83 | POLB (0.55) | MAPTALDH1A1GAASMN1; SMN2LMNA | |
| SCHEMBL5531686 | 0.82 | ALDH1A1 (0.58) | MAPTALDH1A1GAASMN1; SMN2LMNA | |
| SCHEMBL5530231 | 0.78 | POLB (0.58) | MAPTALDH1A1GAASMN1; SMN2LMNA | |
| SCHEMBL5530519 | 0.77 | POLB (0.58) | MAPTALDH1A1GAASMN1; SMN2LMNA | |
| SCHEMBL27782882 | 0.74 | ABCC1 (0.57) | MAPTALDH1A1GAASMN1; SMN2LMNA | |
| SCHEMBL5531303 | 0.73 | PKM (0.56) | MAPTALDH1A1GAASMN1; SMN2LMNA | |
| SCHEMBL5534284 | 0.71 | ABCC1 (0.55) | MAPTALDH1A1GAASMN1; SMN2LMNA | |
| SCHEMBL14906226 | 0.71 | S1PR1 (0.77) | — | |
| SCHEMBL30639441 | 0.70 | SIGMAR1 (0.52) | ALDH1A1GAASMN1; SMN2LMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | ARENA PHARMACEUTICALS, INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010671-A1 | Novel quinazoline derivatives and methods of treatment related to the use thereof | MCHR1, GPR119, MCHR2 | MAPT 680/4885ALDH1A1 2069/4885GAA 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.